Research
Epitalon: what the evidence shows
Search Epitalon and you will find five controlled trials. Open them and every one studies a different substance: a pineal gland extract called Epithalamin, not the four-amino-acid synthetic sold under the Epitalon name. Split the two search terms and the trial count for Epitalon is zero.
- The Epitalon board ranks no provider, and carries the dated regulatory position that explains why.
- Set against another compound on the same evidence standard: MOTS-c vs Epitalon.
Two substances, one search box
Epitalon is a synthetic peptide of four amino acids: alanine, glutamate, aspartate and glycine. It is also written Epithalon, and both spellings refer to the same synthetic molecule.
Epithalamin is something else. It is a polypeptide complex extracted from the pineal gland of animals, and it came first. Epitalon was designed afterwards, based on studying what was in that extract.
FDA states the distinction directly in its own review: Epithalamin is an extracted complex, Epitalon is a tetrapeptide synthesized from the study of its amino acid composition. An extract of an organ and a four-amino-acid synthetic are not interchangeable, and a study of one is not a study of the other.
What splitting the search does to the trial count
Searching the published record in September 2026 for Epitalon, Epithalon and Epithalamin together returns five records tagged as randomized controlled trials. That is the number most citation lists are built on.
Search Epithalamin on its own and the same five appear: 70 records, five controlled trials. Search Epitalon or Epithalon on their own and the picture changes completely. There are 114 records and zero controlled trials.
All five trials belong to the extract. None belongs to the synthetic. Their titles say as much once you look. One is a fifteen-year follow-up of a peptide geroprotector. One reports the effect of a pineal gland peptide preparation on blood pressure in older women. One measures the effect of the preparation Epithalamin on the melatonin rhythm of elderly people. One is a 2003 paper on peptides of the pineal gland and thymus.
The controls confirm the filter is real rather than broken. Through the identical filter in the same session, aspirin returns 5,085 controlled trials, semaglutide returns 303, and a nonsense term returns zero.
The literature is old, and it comes from one tradition
The five trials date from 1999, 2003, 2004, 2008 and 2011. The reference list in FDA's own review is dominated by a small group of authors publishing in Russian gerontology and experimental biology journals across two decades.
A single research tradition producing all the positive results on a compound is not proof of anything wrong. It is a reason to want independent replication before treating a finding as settled, and independent replication is what has not happened here.
Age matters too. Trial reporting standards changed substantially over that period, and a 1999 oncology paper does not carry the detail a reader can assess today.
The use regulators examined was insomnia
Epitalon is sold on longevity claims. Telomeres, cellular aging, pineal function, lifespan. That is the entire pitch.
When it came before the FDA Pharmacy Compounding Advisory Committee in July 2026, the use under evaluation was insomnia. That was the indication the nomination proposed, and the proposed product was a subcutaneous injection.
FDA concluded there is a lack of evidence to support Epitalon for insomnia. It found clinical information discussing effects on melatonin levels or melatonin metabolites, but no studies evaluating the substances in patients with insomnia, particularly by the injection route proposed.
Its reasoning on that point is worth repeating: a change in melatonin levels has an unclear therapeutic meaning without a corresponding measurement of clinical outcomes. A blood marker moving is not the same as a person sleeping better.
The telomere claim, and the concern it creates
The most repeated claim about Epitalon is that it activates telomerase and lengthens telomeres. FDA did not dispute that. It drew the opposite conclusion from it that the marketing does.
The agency's reviewers wrote that Epitalon has the potential to be carcinogenic. Their mechanistic ground was that it has been shown to activate telomerase and lengthen telomeres, and that longer telomeres are generally associated with increased cancer risk.
Whether that risk materializes is unknown, and FDA said why it is unknown. The available animal studies used a single fixed dose, examined female mice only, and exposed them for a short period. Those studies do not adequately inform genotoxic or carcinogenic potential.
Nothing here establishes that Epitalon causes cancer. What it establishes is that the mechanism people buy it for is the same mechanism that makes the missing safety data matter.
Human safety data, and the state of the paperwork
FDA stated there are no clinical data to support the safety of either form of Epitalon in humans, and that it identified no safety data for the subcutaneous route the nomination proposed.
The chemistry side was no better documented. No certificate of analysis for the free base form appeared in the nominations. The information needed to characterize peptide-related impurities, aggregates, and microbial and endotoxin quality was either missing or judged inadequate.
The agency proposed not adding either form of Epitalon to the compounding list. It cited the characterization gaps, the absence of human safety data, immunogenicity concerns, the lack of effectiveness evidence for insomnia, and the existence of approved insomnia treatments.
How this compound is graded here
Epitalon sits in the lowest of the three evidence tiers used on this site: no controlled human evidence. That grade is the direct output of splitting the search term.
Judged on the combined search, the compound would look like it had five controlled trials and a fifteen-year follow-up behind it. Judged on what was actually administered in those trials, it has none.
This is the clearest example on the site of a compound whose apparent evidence base belongs to something else. The Epitalon board carries the dated regulatory position.
Key takeaways
- Epitalon is a synthetic tetrapeptide; Epithalamin is a polypeptide complex extracted from the pineal gland.
- A combined search returns five controlled trials, and all five studied the extract rather than the synthetic.
- Searched on its own, Epitalon returns 114 records and zero randomized controlled trials.
- FDA evaluated Epitalon for insomnia and found no studies in patients with insomnia.
- FDA treated telomerase activation as a carcinogenicity concern, with animal data too limited to resolve it.
- No certificate of analysis for the free base form appeared in the nomination packages.
Frequently asked questions
Are there human trials on Epitalon?
Not on the synthetic tetrapeptide. A September 2026 search for Epitalon or Epithalon alone returns 114 records and no randomized controlled trials. The five controlled trials that appear in a combined search all studied Epithalamin, a polypeptide complex extracted from the pineal gland, which FDA identifies as a different substance. Aspirin returned 5,085 controlled trials through the identical filter in the same session.
What is the difference between Epitalon and Epithalamin?
Epithalamin is extracted from animal pineal glands and is a complex of polypeptides. Epitalon is a single synthetic peptide of four amino acids, designed later on the basis of studying that extract. One is an organ extract, the other a defined synthetic molecule. Evidence for one does not carry to the other, and the two names sit close enough that search results merge them constantly.
Does Epitalon lengthen telomeres?
FDA's review accepted that Epitalon has been shown to activate telomerase and lengthen telomeres. It treated that as a reason for concern rather than reassurance, on the mechanistic ground that longer telomeres are generally associated with increased cancer risk. It also found the available animal studies too limited in dose, sex and duration to say whether that risk is real. Neither an anti-aging benefit nor a cancer risk has been demonstrated in people.
What did regulators actually evaluate Epitalon for?
Insomnia, delivered as a subcutaneous injection. That was the use the nomination proposed. The longevity claims that dominate the market were not the subject of the review. FDA found information on melatonin levels but no studies in patients with insomnia, and noted that a change in a marker without a clinical outcome does not establish a therapeutic effect.
Why does the Epitalon board have no providers on it?
Because a compounded Epitalon product cannot lawfully be dispensed today. A board with rows on it would imply a compliant market that does not exist. The board states the position and carries the date it was checked instead.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- FDA Briefing Document for Epitalon-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee — U.S. Food and Drug Administration, May 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — U.S. Food and Drug Administration, April 2026
- Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people — Bulletin of Experimental Biology and Medicine, April 2004
- Peptides of pineal gland and thymus prolong human life — Neuroendocrinology Letters, June 2003
- PubMed literature census splitting Epitalon from Epithalamin, with a positive control through the same filter — National Library of Medicine, September 2026
- Registered study census for Epitalon and Epithalamin, run with a positive control through the same query — ClinicalTrials.gov, National Library of Medicine, September 2026